Enhancing the Immunogenicity of Vaccinia Virus

Area of Science:

• Virology
• Immunology
• Vaccine Development

Background:

• Conventional vaccinia virus (VACV) vaccines are highly reactogenic, limiting their widespread use.
• There is a need for safer VACV variants with improved immunogenicity to reduce vaccine dosage and adverse effects.
• Genetic modifications targeting viral genes involved in replication and immune evasion can enhance vaccine properties.

Purpose of the Study:

• To evaluate the immunogenicity of VACV LIVP strain variants with modified A34R and A35R genes.
• To compare humoral and T cell-mediated immune responses induced by low-dose VACV variants.
• To determine if combined genetic modifications synergistically enhance VACV immunogenicity.

Main Methods:

• Intradermal immunization of BALB/c mice with low doses (10⁴ pfu/animal) of VACV LIVP and its recombinant variants (LIVP-A34R*, LIVP-dA35R, LIVP-A34R*-dA35R).
• Analysis of humoral immune responses by measuring antibody levels.
• Assessment of T cell-mediated immunity.
• Comparison of immune responses elicited by parental and genetically modified VACV strains.

Main Results:

• The LIVP-A34R*-dA35R variant induced the strongest T cell-mediated immunity.
• The parental LIVP strain showed significantly lower antibody levels compared to modified strains.
• Simultaneous modification of A34R and deletion of A35R genes synergistically enhanced immunogenicity.

Conclusions:

• The VACV LIVP-A34R*-dA35R variant demonstrates superior immunogenic properties compared to the parental strain and single-modified variants.
• Genetic engineering of VACV, specifically targeting genes like A34R and A35R, can significantly improve vaccine efficacy.
• These findings support the development of novel, low-dose VACV-based vaccines with enhanced safety and immunogenicity profiles.